id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id FDA-1975-N-0012-0835,FDA,FDA-1975-N-0012,The American CIeaning Institute Progress Report,Other,Report,2020-12-04T05:00:00Z,2020,12,2020-12-04T05:00:00Z,,2020-12-04T16:11:45Z,,0,0,0900006484986dd3 FDA-1975-N-0012-0834,FDA,FDA-1975-N-0012,FDA Updated Response to ACI July 2020 Progress Report (ethanol bzk pmcx bzec pi),Other,Letter(s),2020-11-23T05:00:00Z,2020,11,2020-11-23T05:00:00Z,,2020-11-23T13:04:07Z,,0,0,0900006484970492 FDA-1975-N-0012-0833,FDA,FDA-1975-N-0012,FDA Response to ACI July 2020 Progress Report (ethanol bzk pmcx bzec pi),Other,Agency Response,2020-11-20T05:00:00Z,2020,11,2020-11-20T05:00:00Z,,2020-11-20T14:36:43Z,,0,0,090000648496ca5e FDA-1975-N-0012-0832,FDA,FDA-1975-N-0012,ACI Advice November 18 2020,Other,Letter(s),2020-11-20T05:00:00Z,2020,11,2020-11-20T05:00:00Z,,2020-11-20T14:31:06Z,,0,0,090000648496c57e FDA-1975-N-0012-0831,FDA,FDA-1975-N-0012,ACI BZT Monograph Meeting Minutes Written Responses,Supporting & Related Material,Meeting Materials,2020-10-06T04:00:00Z,2020,10,,,2020-10-06T14:24:05Z,,0,0,09000064848be3df FDA-1975-N-0012-0830,FDA,FDA-1975-N-0012,Meeting Minutes for Lonza & Henkel’s benzalkonium chloride consumer antiseptic handwash July 30 2020,Other,Minutes,2020-08-26T04:00:00Z,2020,8,2020-08-26T04:00:00Z,,2020-08-26T13:57:23Z,,0,0,09000064848202db FDA-1975-N-0012-0812,FDA,FDA-1975-N-0012,"Lonza Inc. APPROVED BY INTEGREVIEW IRB OCTOBER 25, 2019 THIS IS AN IMPORTANT DOCUMENT - KEEP FOR FUTURE REFERENCE VERSION CONTROL jr/9-27-19 rss/10-25-19 INFORMED CONSENT DOCUMENT AGREEMENT TO BE IN A RESEARCH STUDYre Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use",Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T18:59:45Z,,0,0,0900006484717944 FDA-1975-N-0012-0829,FDA,FDA-1975-N-0012,Lonza Inc. Table 14.1.1: Summary of Subject Enrollment and Disposition re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use,Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T20:15:29Z,,0,0,0900006484718b64 FDA-1975-N-0012-0827,FDA,FDA-1975-N-0012,"Henkel Corporation, Inc. Lonza Inc. A Pilot Maximal Use Study to Measure the Systemic Absorption of Benzalkonium Chloride (BAC) after Exaggerated Use of the Antimicrobial Soap on Intact Skin with Healthy Volunteers re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use",Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T20:15:09Z,,0,0,0900006484718b62 FDA-1975-N-0012-0816,FDA,FDA-1975-N-0012,Lonza Inc. Listing 16.2.2 Protocol Deviations Safety Population (N=42) re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use,Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T19:39:45Z,,0,0,0900006484718732 FDA-1975-N-0012-0819,FDA,FDA-1975-N-0012,Lonza Inc. Listing 16.2.6.1: Hand Wash and Packaging Weights Details Safety Population (N=42) re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use,Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T19:40:29Z,,0,0,0900006484718935 FDA-1975-N-0012-0826,FDA,FDA-1975-N-0012,Lonza Inc. Listing 16.2.12: Comments Safety Population (N=42) re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use,Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T20:04:17Z,,0,0,0900006484718a12 FDA-1975-N-0012-0817,FDA,FDA-1975-N-0012,Lonza Inc. Listing 16.2.4.1: Demographics and Baseline Characteristics Safety Population (N=42) re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use,Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T19:39:55Z,,0,0,0900006484718733 FDA-1975-N-0012-0828,FDA,FDA-1975-N-0012,"Lonza Inc. Figure 14.2.2.1: Individual Subject Plasma Levels, Linear for C12 and C14 homologs, PK Population Subject Number: 0001 at Day 1 re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use",Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T20:15:19Z,,0,0,0900006484718b63 FDA-1975-N-0012-0823,FDA,FDA-1975-N-0012,Lonza Inc. Listing 16.2.9: Physical Examination Results - Abnormal Findings Safety Population (N=42) re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use,Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T19:59:00Z,,0,0,090000648471893e FDA-1975-N-0012-0821,FDA,FDA-1975-N-0012,Lonza Inc. Data Listing 16.2.7.1: Adverse Events Safety Population (N=42) re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use,Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T19:58:43Z,,0,0,090000648471893c FDA-1975-N-0012-0815,FDA,FDA-1975-N-0012,Lonza Inc. Listing 16.2.1 Subject Disposition and Population Inclusion All Enrolled Subjects (N=42) re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use,Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T19:39:36Z,,0,0,0900006484718731 FDA-1975-N-0012-0810,FDA,FDA-1975-N-0012,"Lonza Inc. A Pilot Maximal Use Study to Measure the Systemic Absorption of Benzalkonium Chloride (BAC) After Exaggerated Use of the Antimicrobial Soap on Intact Skin in Healthy Volunteers re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use",Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T18:59:17Z,,0,0,0900006484717942 FDA-1975-N-0012-0813,FDA,FDA-1975-N-0012,Curriculum Vitaes re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use,Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T18:59:58Z,,0,0,0900006484717945 FDA-1975-N-0012-0809,FDA,FDA-1975-N-0012,Lonza Study No_TKL MC000520 CSP Final A Pivotal Maximal Use Study to Measure the Systemic Absorption of Benzalkonium Chloride (BAC) after Exaggerated Use of the Antimicrobial Soap on Intact Skin in Healthy Volunteers,Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T18:59:02Z,,0,0,090000648471742e FDA-1975-N-0012-0811,FDA,FDA-1975-N-0012,"Lonza Inc. Case Report Form Booklet Final Version # 1.0 November 04, 2019 re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use",Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T18:59:35Z,,0,0,0900006484717943 FDA-1975-N-0012-0820,FDA,FDA-1975-N-0012,Lonza Inc. Statistical Analysis Plan re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use,Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T19:58:33Z,,0,0,090000648471849a FDA-1975-N-0012-0822,FDA,FDA-1975-N-0012,Lonza Inc. Listing 16.2.8: Vital Signs Test Results Safety Population (N=42) re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use,Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T19:58:52Z,,0,0,090000648471893d FDA-1975-N-0012-0824,FDA,FDA-1975-N-0012,"Lonza Inc. Listing 16.2.10.1: Laboratory Test Results, Chemistry, Part 1 Safety Population (N=42) re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use",Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T19:59:09Z,,0,0,0900006484718a0f FDA-1975-N-0012-0814,FDA,FDA-1975-N-0012,"Lonza Inc. Signatures of Authors, Principal Investigator, and Sponsor's Medical Officer re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use",Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T19:17:24Z,,0,0,09000064847183f5 FDA-1975-N-0012-0818,FDA,FDA-1975-N-0012,"Lonza Inc. Listing 16.2.5.1: Plasma Concentration (ng/L) - C12 homologs Safety Population (N=42) re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use SORRY",Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T19:40:18Z,,0,0,0900006484718734 FDA-1975-N-0012-0825,FDA,FDA-1975-N-0012,Lonza Inc. Listing 16.2.11: Childbearing Potential and Urine Pregnancy Test Results All Female Subjects (N= 20) re Safety and Effectiveness of Consumer Antiseptics: Topical Antimicrobial Drug Products for Over-the-Counter Human Use,Supporting & Related Material,Background Material,2020-06-29T04:00:00Z,2020,6,,,2020-06-29T20:01:41Z,,0,0,0900006484718a11 FDA-1975-N-0012-0788,FDA,FDA-1975-N-0012,16-5-2-coas-of-reference-standards,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:03:08Z,,0,0,090000648470d126 FDA-1975-N-0012-0787,FDA,FDA-1975-N-0012,16-5-1-preparation-acceptance-criteria-for-cc-qc-sop,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:01:40Z,,0,0,090000648470d125 FDA-1975-N-0012-0797,FDA,FDA-1975-N-0012,16-6-3-ba-3rd-add-to-validationreport,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:17:07Z,,0,0,090000648470d515 FDA-1975-N-0012-0785,FDA,FDA-1975-N-0012,Appendix 2_BAC IVDP Foaming Liquid Handwashes 06.2020 CRL FINAL Report,Supporting & Related Material,Background Material,2020-06-25T04:00:00Z,2020,6,,,2020-06-25T17:09:01Z,,0,0,090000648470c91d FDA-1975-N-0012-0807,FDA,FDA-1975-N-0012,16-5-2-coas-of-reference-standards,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:41:14Z,,0,0,090000648470d834 FDA-1975-N-0012-0800,FDA,FDA-1975-N-0012,16-6-2-ba-2nd-add-to-validationreport,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:40:02Z,,0,0,090000648470d80c FDA-1975-N-0012-0799,FDA,FDA-1975-N-0012,16-6-ba-validationreport,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:39:52Z,,0,0,090000648470d5e5 FDA-1975-N-0012-0796,FDA,FDA-1975-N-0012,16-6-2-ba-2nd-add-to-validationreport,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:15:53Z,,0,0,090000648470d0ff FDA-1975-N-0012-0808,FDA,FDA-1975-N-0012,16-5-1-preparation-acceptance-criteria-for-cc-qc-sop,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:41:23Z,,0,0,090000648470d836 FDA-1975-N-0012-0802,FDA,FDA-1975-N-0012,16-5-bioanalyt-pmut-052019,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:40:28Z,,0,0,090000648470d810 FDA-1975-N-0012-0803,FDA,FDA-1975-N-0012,16-5-6-incurred-samples-reanalysis-sop,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:40:37Z,,0,0,090000648470d812 FDA-1975-N-0012-0790,FDA,FDA-1975-N-0012,16-5-4-representative-chromatograms,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:07:11Z,,0,0,090000648470d128 FDA-1975-N-0012-0805,FDA,FDA-1975-N-0012,16-5-4-result-tables-of-all-runs,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:40:57Z,,0,0,090000648470d830 FDA-1975-N-0012-0786,FDA,FDA-1975-N-0012,Appendix 3_lonza_pmut_052019_csr,Supporting & Related Material,Background Material,2020-06-25T04:00:00Z,2020,6,,,2020-06-25T17:10:56Z,,0,0,090000648470c964 FDA-1975-N-0012-0784,FDA,FDA-1975-N-0012,Appendix 1_Lonza FINAL July 3_2019 Prelim Meeting Preliminary Commt for July 2019 MTG,Supporting & Related Material,Background Material,2020-06-25T04:00:00Z,2020,6,,,2020-06-25T17:09:14Z,,0,0,090000648470c91c FDA-1975-N-0012-0793,FDA,FDA-1975-N-0012,16-5-7-incurred-samples-reanalysis-sop,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:11:20Z,,0,0,090000648470d174 FDA-1975-N-0012-0791,FDA,FDA-1975-N-0012,16-5-5-result-tables-of-all-runs,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:08:19Z,,0,0,090000648470d129 FDA-1975-N-0012-0782,FDA,FDA-1975-N-0012,Briefing Document BAC June 2020_Final,Other,Memo,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T17:00:38Z,,0,0,090000648470c914 FDA-1975-N-0012-0806,FDA,FDA-1975-N-0012,16-5-3-representative-chromatograms,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:41:06Z,,0,0,090000648470d832 FDA-1975-N-0012-0789,FDA,FDA-1975-N-0012,16-5-3-multianalyte-reanalysis-batches-data,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:04:41Z,,0,0,090000648470d127 FDA-1975-N-0012-0804,FDA,FDA-1975-N-0012,16-5-5-Criteria-for-sample-reanalysis-and-reporting-sop,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:40:46Z,,0,0,090000648470d814 FDA-1975-N-0012-0783,FDA,FDA-1975-N-0012,Lonza Study No_TKL MC000520 CSP Final v1.0 19June2020 - signed,Other,Studies,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T17:01:52Z,,0,0,090000648470c915 FDA-1975-N-0012-0792,FDA,FDA-1975-N-0012,16-5-6-Criteria-for-sample-reanalysis-and-reporting-sop,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:10:02Z,,0,0,090000648470d0db FDA-1975-N-0012-0801,FDA,FDA-1975-N-0012,16-6-1-ba-1st-add-to-validationreport,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:40:18Z,,0,0,090000648470d80e FDA-1975-N-0012-0794,FDA,FDA-1975-N-0012,16-5-bioanalyt-pmut-052019,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:12:35Z,,0,0,090000648470d175 FDA-1975-N-0012-0798,FDA,FDA-1975-N-0012,16-6-ba-validationreport,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:18:17Z,,0,0,090000648470d516 FDA-1975-N-0012-0795,FDA,FDA-1975-N-0012,16-6-1-ba-1st-add-to-validationreport,Other,Report,2020-06-25T04:00:00Z,2020,6,2020-06-25T04:00:00Z,,2020-06-25T19:14:43Z,,0,0,090000648470d0fe FDA-1975-N-0012-0781,FDA,FDA-1975-N-0012,MONOGRAPH Meeting Granted Letter Lonza and Henkel 2020 Benzalkonium Hand Soaps,Other,Request,2020-06-24T04:00:00Z,2020,6,2020-06-24T04:00:00Z,,2020-06-24T13:01:00Z,,0,0,0900006484704aa9